

## Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

LOS ANGELES, Sept. 5, 2024 /[PRNewswire](#)/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("*Armata*" or the "*Company*"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D., Chief Executive Officer, will participate in a corporate presentation at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held in New York from September 9-11, 2024.

Armata's presentation is scheduled for Wednesday, September 11, from 8:00-8:30 AM ET.

### **About Armata Pharmaceuticals, Inc.**

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.

### **Media Contacts:**

#### **At Armata:**

Pierre Kyme  
Armata Pharmaceuticals, Inc.  
[ir@armatapharma.com](mailto:ir@armatapharma.com)  
310-665-2928 x234

#### **Investor Relations:**

Joyce Allaire  
LifeSci Advisors, LLC  
[jallaire@lifesciadvisors.com](mailto:jallaire@lifesciadvisors.com)  
212-915-2569

SOURCE Armata Pharmaceuticals, Inc.

---

<https://investor.armatapharma.com/2024-09-05-Armata-Pharmaceuticals-to-Participate-in-the-H-C-Wainwright-26th-Annual-Global-Investment-Conference>